Customer Concentration

6 Months Ended

Jun. 30, 2019

Concentration Risk Disclosure [Text Block]

17. Concentration of Credit Risk

Product Line Concentration

The percentage of total revenue recognized, which individually accounted for 10% or more of the Company’s total revenues in one or more of the periods presented below, was as follows:



	Three Months Ended June 30,		Six Months Ended June 30,
	2019⁽¹⁾	2018	2019⁽¹⁾	2018
Noden	28%	56%	41%	52%
Assertio	49%	20%	39%	20%
LENSAR	20%	13%	19%	13%

^{___________________}


⁽¹⁾	For the three and six months ended June 30, 2019, the AcelRx royalty asset decrease in fair value of $60.0 million and $57.9 million, respectively, are excluded from total revenue when calculating product line concentration.